MedTrace Logo

Performance of Novosyn® in Patients Undergoing Uterus Closure in Cesarean Section

NCT05807633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2023-10-17

No results posted yet for this study

Summary

The aim of this study is to collect clinical data on the use of Novosyn® applied for the uterus closure in cesarean section. Diverse parameters have been selected to assess that the safety and effectiveness of Novosyn® is comparable to published results, where the rate of SSIs in patients undergoing uterus closure in cesarean section was 10.6%.

Conditions

  • Cesarean Section Complications
  • Cesarean Section; Infection

Interventions

DEVICE

Novosyn®

Novosyn® for uterus closure in patients undergoing cesarian section

Sponsors & Collaborators

  • B.Braun Surgical SA

    collaborator INDUSTRY

  • Aesculap AG

    lead INDUSTRY

Principal Investigators

  • Carmen Bergos Sorolla, Dra. · Athaia Xarxa Assistencial Universitaria de Manresa

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-03-28
Completion
2023-10-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05807633 on ClinicalTrials.gov